PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-533.66
Negative P/E while AGEN shows 108.83. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
-218.74
Both companies show negative equity. Martin Whitman would check for industry-wide restructuring opportunities.
-2869.23
Negative FCF while AGEN shows P/FCF of 261.37. Joel Greenblatt would examine cash flow improvement potential.
-3421.96
Negative operating cash flow while AGEN shows P/OCF of 261.37. Joel Greenblatt would examine operational improvement potential.
-218.74
Both companies show negative fair values. Martin Whitman would check for industry-wide valuation issues.
-0.05%
Negative earnings while AGEN shows yield of 0.23%. Joel Greenblatt would examine path to profitability.
-0.03%
Negative FCF while AGEN shows yield of 0.38%. Joel Greenblatt would examine cash flow improvement potential.